Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.42 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193646 | 0.90 | CDK5 (0.45) | DYRK1AGSK3BKIF11CDK5CDK5R1 | |
| SCHEMBL3378612 | 0.87 | TGFBR1 (0.52) | IKBKEPDPK1TGFBR1DYRK1ANFATC1 | |
| SCHEMBL14877206 | 0.87 | CDC7 (0.46) | IKBKEPDPK1TGFBR1DYRK1AGSK3B | |
| Formic Acid SCHEMBL248032 | 0.82 | TGFBR1 (0.47) | IKBKEPDPK1TGFBR1DYRK1ANFATC1 | |
| SCHEMBL2298429 | 0.76 | TRPV1 (0.52) | TGFBR1CYP1A2 | |
| SCHEMBL2302162 | 0.76 | TGFBR1 (0.55) | TGFBR1GSK3BKIF11CHUKCDK5 | |
| SCHEMBL3382050 | 0.76 | IDO1 (0.40) | IKBKEPDPK1TGFBR1GSK3BCDK2 | |
| SCHEMBL3386631 | 0.76 | CDC7 (0.47) | PDPK1DYRK1AGSK3BCDK2DYRK1B | |
| SCHEMBL3390279 | 0.76 | RIPK1 (0.48) | TGFBR1DYRK1AGSK3BKIF11 | |
| SCHEMBL12441314 | 0.75 | MPL (0.44) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | IKBKE 52/4885PDPK1 42/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.